White Paper in Dermatology
Coming soon
Explore our
White Papers
Proposal for the Addition of Adalimumab to the World Health Organization Model List of Essential Medicines for the Treatment of Adults and Children with Severe Psoriasis
Severe psoriasis is a chronic, immune-mediated disease that places a substantial burden on patients and healthcare systems worldwide, particularly in low- and middle-income countries where access to advanced systemic therapies remains limited. This proposal outlines the clinical, public health, and economic rationale for including adalimumab on the WHO Essential Medicines List for the treatment of moderate-to-severe psoriasis in adults and children. Supported by robust evidence on efficacy, safety, real-world use, and cost-effectiveness, the document aims to facilitate more equitable global access to effective systemic psoriasis treatment.
Proposal for the Addition of Ustekinumab to the World Health Organization Model List of Essential Medicines for the Treatment of Adults and Children with Severe Psoriasis
Severe psoriasis is a chronic, immune-mediated disease that places a substantial burden on patients and healthcare systems worldwide, particularly in low- and middle-income countries where access to advanced systemic therapies remains limited. This proposal outlines the clinical, public health, and economic rationale for including ustekinumab on the WHO Essential Medicines List for the treatment of moderate-to-severe psoriasis in adults and children. Supported by extensive evidence on long-term efficacy, safety, real-world use, and cost-effectiveness, the document aims to facilitate more equitable global access to effective systemic psoriasis treatment.